PCDHGA6

Across TCGA pan-cancer cohorts, PCDHGA6 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated PCDHGA6 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PCDHGA6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHGA6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LIHC, SCLC, and UCEC are the cancer types where PCDHGA6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.093	0.720	<.001	29	view →
SCLC	DFS	Median	II,III,IV	0.110	0.578	<.001	24	view →
UCEC	DFS	Median	III,IV	0.922	0.522	.018	16	view →
BLCA	OS	Median	IV	0.180	0.608	<.001	12	view →
PAAD	DFS	Median	All	0.112	0.504	.025	6	view →
LGG	OS	Median	All	0.307	0.811	.008	6	view →
LUAD	OS	Median	All	0.345	0.705	.001	6	view →
PRAD	DFS	Median	All	0.617	0.886	.011	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
COAD	DFS	Median	II,III,IV	0.530	0.789	.016	3	view →
STAD	OS	Median	II,III,IV	0.902	0.661	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

PCDHGA6–LIHC (OS)

Open the LIHC breakdown →